| Oct 2 |
High Growth Tech Stocks In The United States To Watch
|
| Oct 1 |
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
|
| Sep 19 |
Halozyme cut to Neutral at J.P. Morgan on valuation
|
| Sep 16 |
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
|
| Sep 13 |
(HALO) - Analyzing Halozyme Therapeutics's Short Interest
|
| Sep 13 |
Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO™ with ENHANZE® for People with Relapsing and Primary Progressive Multiple Sclerosis
|
| Sep 13 |
Critical Insights From Halozyme Therapeutics Analyst Ratings: What You Need To Know
|
| Sep 13 |
Roche wins FDA nod for Tecentriq version developed with Halozyme
|
| Sep 13 |
Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer
|
| Sep 10 |
Q1 2025 Avid Bioservices Inc Earnings Call
|
